Ireland - English - HPRA (Health Products Regulatory Authority)

flynn pharma limited - rivaroxaban - film-coated tablet - rivaroxaban

Ireland - English - HPRA (Health Products Regulatory Authority)

renata pharmaceuticals (ireland) limited - rivaroxaban - film-coated tablet - rivaroxaban

Ireland - English - HPRA (Health Products Regulatory Authority)

flynn pharma limited - rivaroxaban - film-coated tablet - rivaroxaban

Ireland - English - HPRA (Health Products Regulatory Authority)

flynn pharma limited - rivaroxaban - film-coated tablet - rivaroxaban

Ireland - English - HPRA (Health Products Regulatory Authority)

renata pharmaceuticals (ireland) limited - rivaroxaban - film-coated tablet - rivaroxaban

United States - English - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - rivaroxaban (unii: 9ndf7jz4m3) (rivaroxaban - unii:9ndf7jz4m3) - rivaroxaban 10 mg - xarelto is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. there are limited data on the relative effectiveness of xarelto and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see clinical studies (14.1)]. xarelto is indicated for the treatment of deep vein thrombosis (dvt). xarelto is indicated for the treatment of pulmonary embolism (pe). xarelto is indicated for the reduction in the risk of recurrence of dvt and/or pe in adult patients at continued risk for recurrent dvt and/or pe after completion of initial treatment lasting at least 6 months. xarelto is indicated for the prophylaxis of dvt, which may lead to pe in adult patients undergoing knee or hip replacement surgery. xarelto is indicated for the prophylaxis of venous thromboembolism (vte) and vte related death during hospitalization and post hospital discharge in adult patients admitted for an a

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - rivaroxaban - film-coated tablet - 10 milligram(s) - direct factor xa inhibitors; rivaroxaban

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - rivaroxaban - film-coated tablet - 20 milligram(s) - direct factor xa inhibitors; rivaroxaban

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - rivaroxaban - film-coated tablet - 15 milligram(s) - direct factor xa inhibitors; rivaroxaban

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - apixaban - venous thromboembolism; stroke; arthroplasty - antithrombotic agents - prevention of venous thromboembolic events (vte) in adult patients who have undergone elective hip or knee replacement surgery.prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ≥ ii).treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults (see section 4.4 for haemodynamically unstable pe patients).prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ≥ ii).treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults (see section 4.4 for haemodynamically unstable pe patients).